Physician profile
Katherine A Bloom
NPI 1760697635
$3,719.28
in general payments reported to CMS, 2019-2025
25 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $335 · 2021: $341 · 2022: $580 · 2023: $937 · 2024: $291 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $34.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.75 |
| Education | $34.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $721.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $572.02 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Pfizer INC. | $346.01 | 2019-2025 | |
| Csl Behring | $332.00 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $266.37 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.10 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $187.99 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $139.75 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.33 | 2019-2022 | |
| Optinose US, INC. | $100.09 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $99.26 | 2019-2020 | |
| Kaleo, INC. | $96.02 | 2019-2023 | Auvi-Q |
| Arcutis Biotherapeutics, INC. | $79.04 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $73.43 | 2019 | |
| Alk-Abello, INC | $62.72 | 2019-2023 | Ragwitek, Odactra, Grastek |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.36 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $49.80 | 2020-2022 | |
| Horizon Therapeutics Plc | $38.98 | 2021-2023 | Actimmune |
| Octapharma USA, INC. | $32.24 | 2019-2023 | Cutaquig |
| Covis Pharma Gmbh | $25.41 | 2020 | |
| Leo Pharma INC. | $20.13 | 2024 | Adbry |
| Biocryst US Sales Co., LLC | $19.23 | 2024 | Orladeyo |
| Shire North American Group INC | $17.93 | 2019 | |
| Greer Laboratories, INC. | $16.95 | 2025 | Palforzia |
| Phadia US INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.